Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
How To Invest In The Healthcare Sector
If things go wrong with some healthcare companies, investors often justify why they stay in the stock. And when things go right, they can go right in a hurry. Mersana Therapeutics is an example of how... 
Via Talk Markets
Seagen's Positive Trial Outcomes: Analyst Says The Update Might Double Tukysa's Current Market
Earlier today, Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla)... 
Via Benzinga
Win For Pfizer? Seagen's Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study
Seagen Inc (NASDAQ: SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) met its... 
Via Benzinga
Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
From Seagen Inc.
Via Business Wire
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,600 Today
Via Benzinga
Seagen Earnings Preview
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $17,000 Today
Via Benzinga
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains 
Via MarketBeat
Exposures COVID-19
3 Cheap Long-Term Stocks That Smart Investors Will Snap Up Now
These cheap long-term stocks are a good way to play the current market uncertainty and round out your portfolio. 
Via InvestorPlace
Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
From Seagen Inc.
Via Business Wire
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
How Is The Market Feeling About Seagen?
Via Benzinga
$100 Invested In Seagen 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 20 Years
Via Benzinga
3 Undervalued Large-Cap Stocks That Won't Be for Long
Buying undervalued stocks that have unrealized catalysts will rarely disappoint investors who have the discipline to hold them over time. 
Via MarketBeat
Exposures COVID-19
"Rule Breaker Investing" Market Cap Game Show: A Battle of Wits
Sometimes you know the market cap, sometimes you're just guessing. 
Via The Motley Fool
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
3 Healthcare Stocks With Healthy Dividends
These pharmaceutical companies all combine relatively high dividends with safe payout ratios. 
Via The Motley Fool
Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023
From Seagen Inc.
Via Business Wire
Activision Stock Jumps As U.S. Judge Clears Hurdle To Microsoft Buyout
Activision stock rocketed after a court allowed Microsoft to proceed with its $69 billion acquisition of the video game publisher. 
Via Investor's Business Daily
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
Best Under-the-Radar Stocks: 3 That AI Predicts Will Soar in July
Bard outperformed other AI models and even beat a human reporter in stock picking. It believes these under-the-radar stocks will soar in July. 
Via InvestorPlace
The 7 Most Undervalued S&P 500 Stocks to Buy Now
Undervalued S&P 500 stocks offer the stability of a well-established share at discount prices investors appreciate. 
Via InvestorPlace
Activision Blizzard Shares up 1.83% Amid Regulators' Blunders
Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session. 
Via MarketBeat
Topics Stocks
Exposures US Equities
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Via Benzinga
Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
Unlock the Potential of These 7 Cash-Flow Machines
Here are seven high cash flow stocks that provide investors with both growth and value under any economic conditions. 
Via InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.